Welcome
to the Antibody Engineering Lab
Frederico Aires da Silva
to the Antibody Engineering Lab
Frederico Aires da Silva
Dias JNR, Andre A, Aguiar SA, Ministro J, Peleteiro MC, Rütgen B, Gano L, Correia JDG, Oliveira S, Goncalves J, Gil S, Tavares L, Aires-da-Silva F. Establishment of a bioluminescent canine B-cell lymphoma xenograft model for monitoring tumor progression and treatment response in preclinical studies. PLoS One. 2018 Dec 28;13(12):e0208147. doi: 10.1371/journal.pone.0208147.
18 December 2018
The formal agreement of the Association VectorB2B – Drug Developing – Association for Research in Biotechnology was signed on January 15, 2019. Vector B2B resulted from the shared initiative of seven entities: Medinfar, SA, BEVAG, Faculty of Medicine, Faculty of Pharmacy and Faculty of Veterinary Medicine of the University of Lisbon and the University of Coimbra through the CNC. IBILI, under the coordination of Technophage, SA.
Jan 1, 2019
Ines Rico defended her master’s degree in veterinary sciences by the Faculty of Veterinary Medicine. Her thesis was untitled “Development and optimization of liposomes encapsulated with potent cytotoxic compounds for immunotherapy”.
Jan 17, 2019
Frederico Silva was is Boston attending the Blood-Brain Barrier meeting at the 2019 World Pharm Congress presenting the work “In vivo phage display selections for development of potent blood brain barrier single domain antibodies”.
This work was awarded the Best Presentation Prize. Congratulations to all the BBB team!!!!!!!
Jun 17, 2019
Dias JNR, Lopes M, Peleteiro C, Vicente G, Nunes T, Mateus L, Aires-da-Silva F, Tavares L, Gil S. Canine multicentric lymphoma exhibits systemic and intratumoral cytokine dysregulation. Vet Immunol Immunopathol. 2019 Dec;218:109940. doi: 10.1016/j.vetimm.2019.109940. Epub 2019 Sep 9.
Sep 11, 2019
Frederico Silva (FASLAB) together with Vector B2B Head of Science, Sofia Côrte-Real and its CEO, Miguel Garcia will be attending the Festival of Biologics in Basel, October 15-17, 2019. Meet us at booth 77 to talk about our tailored services along the complete value chain: from target discovery to the clinical trial stage.
Check our website for more information (vectorb2b.com) or reach out directly via email.
Oct 12, 2019
The next week, our students Ana Andre and Marta Silva will attend PEGS Europe in Lisbon to present their work in the CNS and oncology fields.
Please meet our students from Monday to Friday at their posters to learn more about our work. You can also know more about our antibody engineering services provided through VectorB2B. Please meet the VectorB2B team at booth 346.
Nov 10, 2019
Marta Silva defended her master’s degree in Applied Microbiology by Faculty of Science, University of Lisbon. Thesis Title: “Development of a new immunoliposome drug delivery system for treatment of pneumococcal meningitis”.
Isa Moutinho defended her master’s degree in Molecular Biology and Genetics by Faculty of Science, University of Lisbon. Thesis Title:”Development of bispecific antibodies for treatment of HIV infection”.
Maria Ogren defended her master’s degree in Veterinarian Sciences by the Faculty of Veterinary Medicine, University of Lisbon. Thesis Title: Validation of Liposomes in bacterial infections.
Feb 13, 2020
Congratulations to Joana Dias for being awarded a Gilead GENESE grant with the LYMPHOTARGET project.
The LYMPHOTARGET project aims to develop an innovative drug delivery system based on immunoliposomes for the treatment of non-Hodgkin’s lymphoma. By designing antibody-conjugated nanoparticles to selectively target tumor cells and deliver potent antitumor drugs, LYMPHOTARGET aims to establish a novel therapy with a more effective and safer profile for clinical application. The project will be conducted at the FASLab by a multidisciplinary team led by Joana Dias Gomes, in close collaboration with the Institute for Drug Research of the Faculty of Pharmacy, ULisboa.
Feb 20, 2020
Calado R, Duarte J, Borrego P, Marcelino J, Bártolo I, Martin F, Figueiredo I, Almeida S , Graça L, Vítor J, Aires da Silva F, Dias I, Carrapiço B and Taveira N. A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. Vaccines 2020, 8(2), 171; doi.org/10.3390/vaccines8020171. Epub 2020 April 7.
Ministro JH, Oliveira SS, Oliveira JG, Cardoso M, Aires-da-Silva F, Corte-Real S, Goncalves J. Synthetic antibody discovery against native antigens by CRISPR/Cas9-library generation and endoplasmic reticulum screening. Appl Microbiol Biotechnol. 2020 Mar;104(6):2501-2512. doi: 10.1007/s00253-020-10423-3. Epub 2020 Feb 4.
12 April 2020
Next week Frederico Aires da Silva will be attending the PEGS Europe in Barcelona to present our work entitle “In Vivo Phage Display Selections and Rabbit Derived Single-Domain Antibodies as a Promising Platform to Develop Highly Specific and Potent Therapeutic Antibodies”. Please meet Frederico to know more about our work.
Oct 22, 2021
SARS-CoV-2 and the resulting disease, COVID-19, caused economic and global health crises. Vaccination is the main strategy to reduce its spread. However, with the emergence of new variants, new therapeutic strategies are urgently required. Thus, in this project, we aim to develop a novel class of neutralizing antibodies for the treatment and prevention of SARS-CoV-2 infection.
Dec 16, 2021
We will present our antibody platform to develop a new generation of antibody-drug conjugates for the cancer treatment of our pets. Thanks to this opportunity, we will pitch our SmarbAb solution to experts and investors aiming to catapult our start-up to deliver safer and more effective therapeutics for Animal Health. We look forward to meeting everyone in Boston the next week.
16 June 2022
